330 related articles for article (PubMed ID: 28739222)
1. Biomarkers of cancer cachexia.
Loumaye A; Thissen JP
Clin Biochem; 2017 Dec; 50(18):1281-1288. PubMed ID: 28739222
[TBL] [Abstract][Full Text] [Related]
2. Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs.
Belli R; Ferraro E; Molfino A; Carletti R; Tambaro F; Costelli P; Muscaritoli M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445710
[TBL] [Abstract][Full Text] [Related]
3. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.
Miyamoto Y; Hanna DL; Zhang W; Baba H; Lenz HJ
Clin Cancer Res; 2016 Aug; 22(16):3999-4004. PubMed ID: 27340276
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?
Mueller TC; Bachmann J; Prokopchuk O; Friess H; Martignoni ME
BMC Cancer; 2016 Feb; 16():75. PubMed ID: 26856534
[TBL] [Abstract][Full Text] [Related]
6. Cancer cachexia, recent advances, and future directions.
Penet MF; Bhujwalla ZM
Cancer J; 2015; 21(2):117-22. PubMed ID: 25815852
[TBL] [Abstract][Full Text] [Related]
7. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
8. The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes.
Fearon KC
Clin Nutr; 2012 Oct; 31(5):577-82. PubMed ID: 22824237
[TBL] [Abstract][Full Text] [Related]
9. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Fukawa T; Yan-Jiang BC; Min-Wen JC; Jun-Hao ET; Huang D; Qian CN; Ong P; Li Z; Chen S; Mak SY; Lim WJ; Kanayama HO; Mohan RE; Wang RR; Lai JH; Chua C; Ong HS; Tan KK; Ho YS; Tan IB; Teh BT; Shyh-Chang N
Nat Med; 2016 Jun; 22(6):666-71. PubMed ID: 27135739
[TBL] [Abstract][Full Text] [Related]
10. CACHEXIA & BROWN FAT: A BURNING ISSUE IN CANCER.
Kir S; Spiegelman BM
Trends Cancer; 2016 Sep; 2(9):461-463. PubMed ID: 28459108
[TBL] [Abstract][Full Text] [Related]
11. Muscle wasting in cancer and ageing: cachexia versus sarcopenia.
Argilés JM; Busquets S; Felipe A; López-Soriano FJ
Adv Gerontol; 2006; 18():39-54. PubMed ID: 16676797
[TBL] [Abstract][Full Text] [Related]
12. Omics/systems biology and cancer cachexia.
Gallagher IJ; Jacobi C; Tardif N; Rooyackers O; Fearon K
Semin Cell Dev Biol; 2016 Jun; 54():92-103. PubMed ID: 26783720
[TBL] [Abstract][Full Text] [Related]
13. Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment.
Drescher C; Konishi M; Ebner N; Springer J
Int J Cardiol; 2016 Jan; 202():766-72. PubMed ID: 26474466
[TBL] [Abstract][Full Text] [Related]
14. TNF-α and cancer cachexia: Molecular insights and clinical implications.
Patel HJ; Patel BM
Life Sci; 2017 Feb; 170():56-63. PubMed ID: 27919820
[TBL] [Abstract][Full Text] [Related]
15. [Role of Activin A and Myostatin in cancer cachexia].
Thissen JP; Loumaye A
Ann Endocrinol (Paris); 2013 May; 74(2):79-81. PubMed ID: 23566617
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms to explain wasting of muscle and fat in cancer cachexia.
Argilés JM; López-Soriano FJ; Busquets S
Curr Opin Support Palliat Care; 2007 Dec; 1(4):293-8. PubMed ID: 18685378
[TBL] [Abstract][Full Text] [Related]
17. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.
Johns N; Stretch C; Tan BH; Solheim TS; Sørhaug S; Stephens NA; Gioulbasanis I; Skipworth RJ; Deans DA; Vigano A; Ross JA; Bathe OF; Tremblay ML; Kaasa S; Strasser F; Gagnon B; Baracos VE; Damaraju S; Fearon KC
J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):122-130. PubMed ID: 27897403
[TBL] [Abstract][Full Text] [Related]
18. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for Cancer Cachexia: A Mini Review.
Cao Z; Zhao K; Jose I; Hoogenraad NJ; Osellame LD
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925872
[TBL] [Abstract][Full Text] [Related]
20. Definition and classification of cancer cachexia: an international consensus.
Fearon K; Strasser F; Anker SD; Bosaeus I; Bruera E; Fainsinger RL; Jatoi A; Loprinzi C; MacDonald N; Mantovani G; Davis M; Muscaritoli M; Ottery F; Radbruch L; Ravasco P; Walsh D; Wilcock A; Kaasa S; Baracos VE
Lancet Oncol; 2011 May; 12(5):489-95. PubMed ID: 21296615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
